Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
about
Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapsePredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseRelevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseasesFecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?Fecal calprotectin in inflammatory bowel diseaseHow to predict clinical relapse in inflammatory bowel disease patientsOptimizing biologic treatment in IBD: objective measures, but when, how and how often?Disease monitoring in inflammatory bowel diseaseHeterogeneity of the gut microbiome in mice: guidelines for optimizing experimental designBiomarkers as potential treatment targets in inflammatory bowel disease: A systematic reviewProbiotic supplementation in children with cystic fibrosis-a systematic review.Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease.Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies.Inter- and intraobserver agreement in computed tomography enterography in inflammatory bowel disease.The use of fecal calprotectin as a biomarker in gastrointestinal disease.Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.Surgical management of ulcerative colitis in the era of biologicals.Management of inflammatory bowel disease in poor responders to infliximab.Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.Compliance with the faecal calprotectin test in patients with inflammatory bowel disease.Monitoring and detection of disease recurrence after resection for Crohn's disease: the role of non-invasive fecal biomarkers.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.Impact of disease location on fecal calprotectin levels in Crohn's disease.The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases.Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
P2860
Q24658603-BB21A783-A0B3-4438-95D2-96AA9C77DE69Q26745721-85960083-39BA-416C-A398-0E7E6E8E23E5Q26750230-A1B2F39B-F27F-457C-9BC0-116686170BE4Q26765352-CBBCFD67-F5F9-492C-B1C2-235A6F98E377Q26766527-8868CA6F-8159-4D3A-95B5-ADC6A3BBDF3FQ26774575-DDC8819D-FBD9-476D-9C8C-C9D4B883292EQ26775064-7ECAAF14-F664-4913-BDAE-B7DB7460AD63Q26777553-1A36B9E9-F217-4A78-9F99-4B8AF4F97E0EQ26795715-3717E5AA-B3CA-4B04-9EF0-0B89163B6E23Q28087434-CD3912A5-FA55-4AD8-B954-BA175F9853AEQ30248234-0DC42260-9835-43C6-9326-81C533155D74Q33445756-C9C40327-659C-47DA-85AE-96C102B71BF7Q33786052-D4B1EFEC-B47F-41A4-A54E-2143544F4F15Q35044223-BF9AE1AC-C734-4792-9884-81CACD6368E2Q35670680-0362B53D-F775-49EF-9D4E-33916951C6F7Q36155966-55EDF8DB-B27D-49BC-B4FC-E1CD491970ABQ37483425-7882DFF2-0B31-4855-889D-B2851DDBD3B9Q38171862-3E6213B4-DAAD-43E8-AACC-CC7E597030B9Q38190411-4AB4071C-5BD9-4E68-82DD-1B882D337171Q38249428-073CF9D4-3826-4E0C-8862-48CABD0343A2Q38254573-FFCA0F0B-66B7-4C80-A769-26A0441B51E0Q38293787-56DC87F4-7A73-4A5E-A2D2-D4FFD14DB8D6Q38412474-ABBD544E-E306-4477-8911-5B5155F04597Q38492052-155F6A16-B98D-45E5-82E5-047CD8266BA7Q38641380-6C2A4EA1-074D-4C2A-A9D8-F80C92D30AD4Q38657630-A2C1F809-8E57-4390-94DB-6492C172243EQ38673082-D48E8EB8-01BE-42D4-A7C7-C33C7F2EF7E2Q38742261-486FCE68-2450-4375-9A4B-C98EC6AFFA74Q38774391-10F2C350-FBAE-4D30-854D-E02494AC432DQ38782416-64D5B194-C5EC-4583-833D-85CC3C701BEBQ39077823-9862179A-AC9D-4C77-9FC6-1B1AC427AFF5Q39179611-603A0758-5294-4359-AFB5-54581757917BQ39612269-22857D28-0C6A-4B2F-B0DE-6E2D00BC21AEQ40038096-14E94AFD-D9FB-4B5D-BA5E-05EBD873DD05Q40288099-E2D2D919-CE14-4529-A1BD-27F1DDCA1FFFQ40295402-02A3EC2D-8A31-4C63-B970-12B14083BDDAQ40460090-8CA14D22-70E9-49C5-AF68-4B0AFC34F44FQ41504176-8AB2C09B-C0BC-435B-AF6E-B765BB67400EQ41587613-A4CA2D2D-EA7F-4B6E-8D08-769EF620EC43Q41821193-8580D5BA-7891-4468-A9B7-FFED1213AC63
P2860
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Consecutive fecal calprotectin ...... nfliximab maintenance therapy.
@en
Consecutive fecal calprotectin ...... nfliximab maintenance therapy.
@nl
type
label
Consecutive fecal calprotectin ...... nfliximab maintenance therapy.
@en
Consecutive fecal calprotectin ...... nfliximab maintenance therapy.
@nl
prefLabel
Consecutive fecal calprotectin ...... nfliximab maintenance therapy.
@en
Consecutive fecal calprotectin ...... nfliximab maintenance therapy.
@nl
P2093
P2860
P50
P1476
Consecutive fecal calprotectin ...... infliximab maintenance therapy
@en
P2093
André Van Gossum
Arnaud Collard
Bart Neuville
Bert J K Vander Cruyssen
Denis Franchimont
Dirk A J Staessen
Edouard J Louis
Eirik Kittang
Fazia Mana
Fernand Fontaine
P2860
P304
P356
10.1097/MIB.0B013E31829B2A37
P577
2013-09-01T00:00:00Z